金陵药业(000919) - 2024 Q4 - 年度业绩预告

Financial Performance Forecast - The estimated net profit for 2024 is projected to be between 36 million and 53 million yuan, representing a decline of 46.82% to 63.87% compared to the previous year[3]. - The net profit after deducting non-recurring gains and losses is expected to be between 42 million and 62 million yuan, indicating a decrease of 27.68% to 51.01% year-over-year[3]. - Basic earnings per share are forecasted to be between 0.0608 yuan and 0.0895 yuan, down from 0.1977 yuan in the previous year[3]. - The decline in net profit is attributed to changes in the scope of consolidation, increased R&D expenses, and reduced profits in the medical and health care sector due to policy reforms[7]. Acquisition and Consolidation - The company completed the acquisition of a 51% stake in Nanjing Meishan Hospital, which will be consolidated into the company's financial statements[4]. - The net profit from Nanjing Meishan Hospital will be classified as non-recurring gains and losses for the 2024 fiscal year[7]. Communication and Reporting - The company has communicated with its accounting firm regarding the performance forecast and found no significant discrepancies[6]. - The performance forecast data is preliminary and subject to change, with the final figures to be disclosed in the 2024 annual report[8].